During the following hours, we are asking residents to come by our booth and play Z-Ball
with us to see who makes it to the top of the leaderboard! Will it be you?
FRIDAY, MARCH 27, 2026 | 11:00 AM - 12:00 PM
MST
SATURDAY, MARCH 28, 2026 | 11:00 AM - 12:00
PM MST
SUNDAY, MARCH 29, 2026 | 10:30 AM - 11:30 AM
MST
Podcast Booth Photos Sit at the Mic at Studio Z
Podcast Booth Photos Sit at the Mic at Studio
Z
When podcasts aren't in session, stop by and step inside to experience Studio Z—take a
photo or capture a video.
Connect With Us
Connect With Us
Interested in meeting with us? Reach out via the email address.
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B
or
C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire,
flame,
and smoking during and immediately following application.
The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for
pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract
infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%),
and
headache (1.1%).
The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for
patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%),
application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for
plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%),
application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract
infection (1.0%).
The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for
plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis
(1.3%).
The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for
seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate
atopic dermatitis in pediatric patients 2 to 5 years of age.
ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate
atopic dermatitis in adult and pediatric patients 6 years of age and older.
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis,
including intertriginous areas, in adult and pediatric patients 6 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis
of the scalp and body in adult and pediatric patients 12 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic
dermatitis in adult and pediatric patients 9 years of age and older.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
ZORYVE is contraindicated in patients with moderate to severe liver impairment
(Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid
fire,
flame, and smoking during and immediately following application.
The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for
pediatric
patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract
infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis
(1.4%), and headache (1.1%).
The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients
with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%),
application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque
psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%),
application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary
tract infection (1.0%).
The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque
psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis
(1.3%).
The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic
dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic
dermatitis in pediatric patients 2 to 5 years of age.
ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic
dermatitis in adult and pediatric patients 6 years of age and older.
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis,
including
intertriginous areas, in adult and pediatric patients 6 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the
scalp and body in adult and pediatric patients 12 years of age and older.
ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis
in
adult and pediatric patients 9 years of age and older.
